Dispatches from the Cain Brothers MedTech, Life Sciences and Pharma Services CEO Conference | Life Sciences Snapshot Q2 2026

U.S. life sciences deal activity was relatively muted in Q1 of 2026, one of the slowest quarters in the last five years. There were some pockets of resilience, for example new company formation structures have enabled Chinese pharmaceutical companies to access US capital, and AI is enabling a new wave of startup growth and innovation. IPO momentum suggests that public listings could rebound in 2026.

Read Orrick’s Q2 2026 Life Sciences Snapshot for insights on these trends, and what this means for founders navigating an unpredictable exit environment. This issue includes a roundtable focused on “Preparing for an Exit”, a follow-on to an Orrick-hosted panel discussion held April 9th, 2026 at the Cain Brothers MedTech, Life Sciences and Pharma Services CEO Conference in Aspen, Colorado.

Read the report (24 minute read)

Contact Us